A family history of prostate cancer has been shown to be one of the most important determinants of prostate cancer risk. Using segregation analysis, investigators have demonstrated that early-onset prostate cancer in some families may be explained by autosomal dominant inheritance of a rare susceptibility allele. The first putative genetic locus associated with the inherited predisposition to prostate cancer, referred to as HPCl at chromosome 1q24-25, was recently identified through analysis of a set of high-risk prostate cancer families. Analysis of an independent set of families in our laboratory has also revealed evidence of prostate cancer linkage to chromosome 1q markers. Prostate cancer is an exceedingly important health problem for African American men, since the age-adjusted incidence of prostate cancer in African American men is approximately fifty percent greater than in Caucasian American men. The relative risk associated with a family history of prostate cancer is similar between African and Caucasian American men emphasizing the importance of predisposing germline mutations in both ethnic cohorts. African American families, however, have been under-represented in studies of the inherited predisposition to prostate cancer. Furthermore, analysis of six African American families in our laboratory suggests that HPCl may be particularly important in this population. To test the hypothesis that HPCl contributes to prostate cancer predisposition in African American families, the following Specific Aims are proposed: I. Identify African American families with two or more living family members affected with prostate cancer. II. Isolate DNA and genotype all individuals identified at Specific Aim I using a panel of polymorphic markers spanning the HPCl candidate interval. III. Use parametric and non-parametric multipoint analysis to assess for linkage of prostate cancer to markers that map to 1q24-25. IV. Collect all available tumor samples from prostate cancer patients for analysis of loss of heterozygosity (LOH), a characteristic of many tumor suppressor genes, at 1q24-25. If the HPCl gene is cloned within the time frame of this proposal, additional experiments are proposed to characterize potential HPCl mutations and to test for linkage to other potential prostate cancer susceptibility loci in families with prostate cancer that is not due to mutations in the HPCl gene.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA069568-04
Application #
6103204
Study Section
Project Start
1998-09-30
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 527 publications